Bank of America, Merrill Lynch and HSBC Bank plc are Coordinating Bookrunners and Mandated Lead Arrangers for the facility.
The syndicate also includes Barclays Bank PLC, BNP Paribas, Citibank N.A., Credit Suisse AG, Goldman Sachs Bank USA, JPMorgan Chase Bank N.A., Mizuho Bank LTD., Morgan Stanley Bank N.A., Morgan Stanley Senior Funding, INC., MUFG Bank LTD., Sumitomo Mitsui Banking Corp. and PNC Bank National Association as Bookrunners and Mandated Lead Arrangers, and Banca IMI as lead arranger.
Teva Pharmaceutical is in generic medicines, but has innovative treatments in select areas, including CNS, pain and respiratory.
The company has an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R and D function, strong operational base and global infrastructure and scale.
Headquartered in Israel, with production and research facilities around the globe, Teva employs 45,000 professionals, committed to improving the lives of millions of patients.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib